2026-10-29
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA® BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with the U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally.